Heart Pump Devices Market Analysis 2026

New Jersey's NYU Langone Health has completed the first transplant surgery to combine a mechanical heart pump and a gene-edited pig kidney. Lisa Pisano, 54, had heart failure and end-stage kidney disease that required routine dialysis. She couldn't have a standard heart or kidney transplant due to other chronic medical conditions and an overall lack of donor organs in the US. Experts believe xenotransplants, transplants of animal organs into people, are crucial to solving the organ shortage. Gene editing makes precise edits to a pig's DNA to help keep the human body from recognizing the animal's organs as foreign and rejecting them. Pisano received the heart pump on April 4 and then received a gene-edited pig kidney along with the pig's thymus gland. Her case is the first reported organ transplant in a person with a mechanical heart pump, and the second known transplant of a gene-edited pig kidney into a living recipient and the first transplanted along with the thymus. The kidney came from a pig genetically engineered to disrupt a gene responsible for the production of a sugar found on the surface of animal cells called alpha-gal, which can be recognized by human antibodies and attacked.

The manufacturer of miniature pumps, Abiomed, has released the first encouraging findings of a randomised study that indicated higher six-month survival rates for patients with acute myocardial infarction and cardiogenic shock. A control arm that got conventional care only was compared to a group of patients who received extra treatment using Abiomed's Impella CP catheter-based pump, in this 355-person research conducted in the UK, Denmark, and Germany. In the latter group, 103 out of 176 patients passed away within six months for any reason, and 82 out of 179 patients, or 45.8%, died after obtaining an Impella CP pump. This translated into a 12.7% statistically significant decrease in 180-day mortality. About 10% of patients who experience a heart attack brought on by a blocked coronary artery—also referred to as an ST-elevated myocardial infarction, or STEMI—come into life-threatening cardiogenic shock, frequently within a day. STEMIs are associated with mortality rates ranging from 40% to 50%. In this patient group, three earlier smaller randomised trials were unable to demonstrate any discernible benefits. Abiomed will keep researching the use of Impella CP in STEMI cases, paying particular attention to when the treatment should be started and where the pump should be placed before starting a PCI procedure.